Valuation models
price $412.62 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused119.94 – 163.40138.23199% overvaluedDCF · Perpetuity growth · 10y129.18 – 176.67149.16177% overvaluedDCF · EBITDA exit · 5y324.03 – 353.07338.1622% overvaluedDCF · EBITDA exit · 10y287.46 – 337.86311.4332% overvaluedP/E · peers237.32 – 773.47379.089% overvaluedP/E · own history288.81 – 380.65332.9424% overvaluedPEG—146.76181% overvaluedEV/EBITDA · peers162.79 – 219.44187.20120% overvaluedEV/Revenue · peers94.90 – 295.52198.03108% overvaluedEarnings power value49.42 – 66.3356.52630% overvaluedDividend discount13.08 – 29.9518.772098% overvaluedWall St. consensus target—415.001% belowCost of capital (WACC)—9.35%—
DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. How the headline model is chosen. The price is 199% above the model value: the models see only the filed business, and a company priced on businesses with no revenue line yet is better taken apart, as Tesla is.
Model value · DCF · Perpetuity growth · 5y
138.23
West Pharmaceutical Services closed at $412.62 — overvalued by 199% vs model.
119.94the model's range163.40
DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
18.77 – 379.08
Wall St. target
415.00 1% below
Above model, 1y
30 of 30 days
How it is valued
Valued asMature & Stable
Low/slowing growth (~2% recent)Moderate margins (16% net margin)Highly cyclical earnings
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.